Intercure Ltd
INCR
Company Profile
Business description
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Contact
85 Medinat ha-Yehudim Street
Herzliya4676670
ISRT: +972 774605012
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
320
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,815.30 | 5.00 | -0.06% |
| CAC 40 | 7,794.49 | 34.80 | -0.44% |
| DAX 40 | 24,038.96 | 216.35 | -0.89% |
| Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
| FTSE 100 | 8,978.33 | 37.21 | 0.42% |
| HKSE | 24,203.32 | 63.75 | 0.26% |
| NASDAQ | 20,585.53 | 45.14 | -0.22% |
| Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
| NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
| S&P 500 | 6,259.75 | 20.71 | -0.33% |
| S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
| SSE Composite Index | 3,519.65 | 9.47 | 0.27% |